Extravan

Treatment for Glaucoma

Alcon Receives Approvable Letter for Extravan

FORT WORTH, Texas--September 17, 2004 - Alcon, Inc. (NYSE:ACL) today announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for Extravan ophthalmic solution for the treatment of glaucoma. Extravan solution is a fixed combination of travoprost 0.004 percent and timolol 0.5 percent.

"We will be meeting with the FDA as soon as possible to clarify what additional steps may be required to gain final approval to market Extravan," said Dr. Scott Krueger, Alcon's Vice President of Regulatory Affairs.

Alcon is the world's leading eye care company and has been dedicated to the ophthalmic industry for more 57 years. Alcon develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye.

For further information, please visit www.alconinc.com

Posted: September 2004

Related Articles

Extravan (travoprost and timolol ) FDA Approval History

View comments

Hide
(web1)